- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04775329
Primary Prophylaxis for Spontaneous Bacterial Peritonitis (SIBOC)
January 4, 2023 updated by: Changi General Hospital
Primary Prophylaxis for Spontaneous Bacterial Peritonitis in Decompensated Chronic Liver Disease With Small Bowel Bacterial Overgrowth: A Randomised Trial
Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth (SIBO) yet may be asymptomatic.
It is unclear as to the value of treating SIBO in asymptomatic individuals.
Cirrhosis increase permeability of the gastrointestinal mucosa.
It is postulated that in cirrhosis, endotoxins translocate across the gut mucosal barrier resulting in a second hit within hepatocyte perpetuating decompensation and spontaneous bacterial peritonitis.
We hypothesise that cirrhosis patients with concomitant SIBO are particularly vulnerable for endotoxin translocation and would benefit from treatment.
Treatment of SIBO would reduce the risk of spontaneous bacterial peritonitis and other liver-related morbidities.
We aim to treat a cohort of patients with severe liver disease and concomitant SIBO with antibiotics as prophylaxis and compare the risk of spontaneous bacterial peritonitis, further liver-related morbidity and survival against untreated asymptomatic controls.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore, 529889
- Wong Yu Jun
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Decompensated liver cirrhosis (Childs B & C) with ascites.
- Established diagnosis of SIBO
Exclusion Criteria:
- Known allergy to treatment drugs
- Inability to undergo test confirm the success of SIBO eradication;
- Pregnant or lactating women
- Terminal malignancy.
- Untreated Viral Hepatitis
- Alcoholic Liver disease with ongoing drinking.
- Respiratory Failure
- Recent antibiotics and proton-pump inhibitor within 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control arm
Standard of care
|
|
Active Comparator: Treatment arm
|
Rifaximin 1000mg OM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Spontaneous bacterial peritonitis
Time Frame: 12 months
|
To determine the rate of cirrhosis-related complications, with and without Rifaximin among decompensated cirrhosis with SIBO.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of all liver related events (hepatic encephalopathy, variceal bleeding, acute on chronic liver failure)
Time Frame: 12 months
|
To study and understand the immunophysiological and gut microbiota changes associated with bowel decontamination among cirrhosis patients with SIBO using serum biomarkers.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: YU JUN WONG, MD, MRCP FAMS, Changi General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2020
Primary Completion (Actual)
January 1, 2023
Study Completion (Actual)
January 1, 2023
Study Registration Dates
First Submitted
January 25, 2021
First Submitted That Met QC Criteria
February 25, 2021
First Posted (Actual)
March 1, 2021
Study Record Updates
Last Update Posted (Estimate)
January 6, 2023
Last Update Submitted That Met QC Criteria
January 4, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIBOC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Decompensated Cirrhosis
-
Region StockholmSahlgrenska University Hospital, SwedenRecruitingHemostasis in Decompensated Liver Cirrhosis | Inflammation in Decompensated Liver CirrhosisSweden
-
University College, LondonLondon School of Hygiene and Tropical Medicine; CyberLiver LtdRecruitingDecompensated CirrhosisUnited Kingdom
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Beijing 302 HospitalVCANBIO Cell & Gene Engineering Corporation, LtdRecruitingDecompensated CirrhosisChina
-
Beijing 302 HospitalLanZhou University; Chinese PLA General Hospital; Third Affiliated Hospital,... and other collaboratorsNot yet recruitingDecompensated CirrhosisChina
-
Chinese Academy of SciencesThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...UnknownDecompensated CirrhosisChina
-
Zagazig UniversityCompletedDecompensated Cirrhosis
-
Institute of Liver and Biliary Sciences, IndiaUnknown
-
Shandong Qilu Stem Cells Engineering Co., Ltd.First Affiliated Hospital of Fujian Medical University; Shanghai Public Health... and other collaboratorsUnknownDecompensated Liver Cirrhosis
-
Institute of Liver and Biliary Sciences, IndiaCompleted
Clinical Trials on Rifaximin
-
Bausch Health Americas, Inc.CompletedIrritable Bowel Syndrome With DiarrheaUnited States, United Kingdom, Germany
-
Bausch Health Americas, Inc.CompletedSickle Cell DiseaseUnited States, Canada, Kenya
-
Bausch Health Americas, Inc.CompletedLiver CirrhosisUnited States, Russian Federation
-
Alfasigma S.p.A.TerminatedDiverticulitisFrance, Germany, Italy, Netherlands, Spain, United Kingdom
-
Bausch Health Americas, Inc.CompletedOvert Hepatic EncephalopathyUnited States
-
SandozTerminatedTravelers' DiarrheaMexico
-
National University Hospital, SingaporeNational University, SingaporeCompletedIrritable Bowel Syndrome With DiarrheaSingapore
-
Shanghai Changzheng HospitalUnknown
-
Sun Yat-sen UniversityRecruitingHepatic Encephalopathy | Hepatitis B | HBV | Effect of Drug | Liver Failure, Acute on Chronic | RifaximinChina
-
Bausch Health Americas, Inc.Active, not recruitingHepatic EncephalopathyUnited States, Australia, Canada, Puerto Rico